AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid
AbbVie has cut a deal worth up to $745m with Chinese biopharmaceutical company, Haisco, to bolster its pain pipeline amid…
13 Apr 2026
Telix and Regeneron sign $4.3bn deal to co-develop radiopharmaceutical therapies
Telix and Regeneron Pharmaceuticals have entered a partnership worth up to $4.3bn for the development and commercialisation of new radiopharmaceutical therapies. This collaboration aims to integrate Telix's expertise in radiopharmaceutical…
13 Apr 2026
FDA issues complete response letter to Replimune’s RP1 for melanoma
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Replimune Group’s biologics licence application (BLA) concerning the RP1 therapy in combination with nivolumab for…
10 Apr 2026
BMS and Oxford BioTherapeutics join forces in TCE discovery pact
Bristol Myers Squibb (BMS) and Oxford BioTherapeutics (OBT) have forged an alliance to discover and develop new T-cell engager (TCE) therapies for solid tumours – building on the latter company’s…
10 Apr 2026
Roche and C4 Therapeutics to advance degrader-antibody conjugates research
Roche has signed a new collaboration agreement with C4 Therapeutics to jointly advance research in the field of degrader-antibody conjugates (DACs), aiming to introduce a new therapeutic modality for cancer.…
10 Apr 2026
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
Gan & Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the clinical development, regulatory approval, and commercialisation of bofanglutide injection in South Korea. Bofanglutide is a…
09 Apr 2026
EverSea Medicines to acquire Hasten Biopharmaceuticals
Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten Biopharmaceuticals (Asia). The acquisition aims to enhance…